Induction therapy: are we picking our battles?

Editorial

Anil Chandraker et al. Clin J Am Soc Nephrol. 2006 May.

. 2006 May;1(3):356-7.

doi: 10.2215/CJN.00900306. Epub 2006 Apr 12.

No abstract available

Comment on

Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
Gallon L, Gagliardini E, Benigni A, Kaufman D, Waheed A, Noris M, Remuzzi G. Gallon L, et al. Clin J Am Soc Nephrol. 2006 May;1(3):539-45. doi: 10.2215/CJN.01741105. Epub 2006 Apr 5. Clin J Am Soc Nephrol. 2006. PMID: 17699257
Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
Ruggenenti P, Codreanu I, Cravedi P, Perna A, Gotti E, Remuzzi G. Ruggenenti P, et al. Clin J Am Soc Nephrol. 2006 May;1(3):546-54. doi: 10.2215/CJN.01841105. Epub 2006 Mar 1. Clin J Am Soc Nephrol. 2006. PMID: 17699258 Clinical Trial.